BACKGROUND: Drinking during pregnancy has been associated with learning disabilities in affected offspring. At present, there are no clinically effective pharmacotherapeutic interventions for these learning deficits. Here, we examined the effects of ABT-239, a histamine H₃ receptor antagonist, on fetal ethanol-induced fear conditioning and spatial memory deficits. METHODS AND RESULTS: Long-Evans rat dams stably consumed a mean of 2.82 g ethanol/kg during a 4-hour period each day during pregnancy. This voluntary drinking pattern produced a mean peak serum ethanol level of 84 mg/dl. Maternal weight gain, litter size and birth weights were not different between the ethanol-consuming and control groups. Female adult offspring from the control and fetal alcohol-exposed (FAE) groups received saline or 1 mg ABT-239/kg 30 minutes prior to fear conditioning training. Three days later, freezing time to the context was significantly reduced in saline-treated FAE rats compared to control. Freezing time in ABT-239-treated FAE rats was not different than that in controls. In the spatial navigation study, adult male offspring received a single injection of saline or ABT-239 30 minutes prior to 12 training trials on a fixed platform version of the Morris Water Task. All rats reached the same performance asymptote on Trials 9 to 12 on Day 1. However, 4 days later, first-trial retention of platform location was significantly worse in the saline-treated FAE rats compared control offspring. Retention by ABT-239-treated FAE rats was similar to that by controls. ABT-239's effect on spatial memory retention in FAE rats was dose dependent. CONCLUSIONS: These results suggest that ABT-239 administered prior to training can improve retention of acquired information by FAE offspring on more challenging versions of hippocampal-sensitive learning tasks. Further, the differential effects of ABT-239 in FAE offspring compared to controls raises questions about the impact of fetal ethanol exposure on histaminergic neurotransmission in affected offspring.
BACKGROUND: Drinking during pregnancy has been associated with learning disabilities in affected offspring. At present, there are no clinically effective pharmacotherapeutic interventions for these learning deficits. Here, we examined the effects of ABT-239, a histamine H₃ receptor antagonist, on fetal ethanol-induced fear conditioning and spatial memory deficits. METHODS AND RESULTS: Long-Evans rat dams stably consumed a mean of 2.82 g ethanol/kg during a 4-hour period each day during pregnancy. This voluntary drinking pattern produced a mean peak serum ethanol level of 84 mg/dl. Maternal weight gain, litter size and birth weights were not different between the ethanol-consuming and control groups. Female adult offspring from the control and fetal alcohol-exposed (FAE) groups received saline or 1 mg ABT-239/kg 30 minutes prior to fear conditioning training. Three days later, freezing time to the context was significantly reduced in saline-treated FAErats compared to control. Freezing time in ABT-239-treated FAErats was not different than that in controls. In the spatial navigation study, adult male offspring received a single injection of saline or ABT-239 30 minutes prior to 12 training trials on a fixed platform version of the Morris Water Task. All rats reached the same performance asymptote on Trials 9 to 12 on Day 1. However, 4 days later, first-trial retention of platform location was significantly worse in the saline-treated FAErats compared control offspring. Retention by ABT-239-treated FAErats was similar to that by controls. ABT-239's effect on spatial memory retention in FAErats was dose dependent. CONCLUSIONS: These results suggest that ABT-239 administered prior to training can improve retention of acquired information by FAE offspring on more challenging versions of hippocampal-sensitive learning tasks. Further, the differential effects of ABT-239 in FAE offspring compared to controls raises questions about the impact of fetal ethanol exposure on histaminergic neurotransmission in affected offspring.
Authors: Rafael K Varaschin; Katherine G Akers; Martina J Rosenberg; Derek A Hamilton; Daniel D Savage Journal: J Pharmacol Exp Ther Date: 2010-03-22 Impact factor: 4.030
Authors: Gerard B Fox; Jia Bao Pan; Timothy A Esbenshade; Youssef L Bennani; Lawrence A Black; Ramin Faghih; Arthur A Hancock; Michael W Decker Journal: Behav Brain Res Date: 2002-04-01 Impact factor: 3.332
Authors: Rafael K Varaschin; Katherine G Akers; Martina J Rosenberg; Derek A Hamilton; Daniel D Savage Journal: J Pharmacol Exp Ther Date: 2010-03-22 Impact factor: 4.030
Authors: Rafael K Varaschin; Nyika A Allen; Martina J Rosenberg; C Fernando Valenzuela; Daniel D Savage Journal: Alcohol Clin Exp Res Date: 2018-01-08 Impact factor: 3.455
Authors: Derek A Hamilton; Daniel Barto; Carlos I Rodriguez; Christy M Magcalas; Brandi C Fink; James P Rice; Clark W Bird; Suzy Davies; Daniel D Savage Journal: Behav Brain Res Date: 2014-04-24 Impact factor: 3.332
Authors: B Lewis; K A Wellmann; A M H Kehrberg; M L Carter; T Baldwin; M Cohen; S Barron Journal: Pharmacol Biochem Behav Date: 2011-10-20 Impact factor: 3.533
Authors: Rafael K Varaschin; Martina J Rosenberg; Derek A Hamilton; Daniel D Savage Journal: Alcohol Clin Exp Res Date: 2014-05-12 Impact factor: 3.455
Authors: James P Rice; Lisa E Suggs; Alexandra V Lusk; Matthew O Parker; Felicha T Candelaria-Cook; Katherine G Akers; Daniel D Savage; Derek A Hamilton Journal: Alcohol Date: 2012-06-27 Impact factor: 2.405